Losartan and renal failure
Pro Research Analysisby 
Searched over 200M research papers
Losartan and Renal Failure: A Comprehensive Overview
Introduction to Losartan and Renal Failure
Losartan, an angiotensin II receptor antagonist, is widely used to manage hypertension and protect renal function. Its role in patients with chronic renal failure (CRF) and diabetic nephropathy has been extensively studied, revealing significant benefits and some risks. This article synthesizes the findings from multiple studies to provide a clear understanding of losartan's effects on renal health.
Losartan's Impact on Diabetic Nephropathy
Renal Benefits in Type 2 Diabetes
Losartan has shown significant renal benefits in patients with type 2 diabetes and nephropathy. A large-scale study involving 1513 patients demonstrated that losartan reduced the incidence of a doubling of serum creatinine concentration by 25% and end-stage renal disease (ESRD) by 28% compared to placebo . Additionally, losartan significantly decreased proteinuria by 35%, indicating its protective effect on kidney function .
Long-term Renoprotection
Further analysis of the RENAAL trial indicated that losartan's renoprotective effects extend across all stages of type 2 diabetic nephropathy. The drug reduced the risk of ESRD and hospitalizations for heart failure, and it was well tolerated even in patients with advanced chronic kidney disease . This suggests that losartan is a suitable treatment option for diabetic patients at various stages of renal impairment.
Losartan in Chronic Renal Failure
Antihypertensive and Sympathetic Activity Reduction
In hypertensive patients with chronic renal failure, losartan effectively reduces blood pressure and muscle sympathetic nerve activity (MSNA). A study comparing losartan with enalapril found that both drugs equally reduced MSNA and blood pressure, highlighting the role of angiotensin II in sympathetic hyperactivity in CRF patients .
Acute GFR Changes and Long-term Outcomes
An acute fall in glomerular filtration rate (GFR) during the initial phase of losartan treatment has been observed. However, this initial decline is associated with a slower long-term decrease in renal function, suggesting a beneficial hemodynamic effect . This finding emphasizes the importance of monitoring GFR changes during the early stages of losartan therapy.
Losartan's Protective Mechanisms
Antioxidant and Anti-inflammatory Effects
Losartan's benefits extend beyond blood pressure control. In experimental models of chronic renal failure, a losartan-antioxidant hybrid (GGN1231) demonstrated reduced proteinuria, inflammation, and fibrosis, indicating potential advantages in managing cardiovascular and inflammatory processes . Additionally, losartan improved antioxidant defense and reduced oxidative stress in postischemic hypertensive kidneys, further supporting its protective role .
Dopaminergic and Renin-Angiotensin System Balance
Losartan also helps maintain the balance between the renal dopaminergic system (RDS) and the renin-angiotensin system (RAS). In conditions like fructose overload-induced hypertension and kidney damage, losartan prevented metabolic and hemodynamic alterations, reduced pro-inflammatory markers, and preserved renal function .
Risks and Considerations
Potential for Renal Impairment
Despite its benefits, losartan can cause renal impairment in certain patients. A case report highlighted a significant increase in serum creatinine and blood urea nitrogen levels in a patient with preexisting renal impairment and other risk factors, which normalized after discontinuing losartan . This underscores the need for careful monitoring in patients at risk for renal failure.
Long-term Safety in Renal Transplant Recipients
In renal transplant recipients, losartan effectively managed hypertension and significantly reduced proteinuria without adversely affecting graft function. However, a notable side effect was a reduction in hemoglobin levels, which requires monitoring during long-term therapy .
Conclusion
Losartan offers substantial renal protection and antihypertensive benefits in patients with chronic renal failure and diabetic nephropathy. Its ability to reduce proteinuria, manage blood pressure, and provide antioxidant and anti-inflammatory effects makes it a valuable therapeutic option. However, careful monitoring is essential, especially in patients with preexisting renal impairment or those at risk for renal failure. Overall, losartan remains a well-tolerated and effective treatment for preserving renal function in various patient populations.
Sources and full results
Most relevant research papers on this topic
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Losartan significantly reduces the risk of kidney damage and end-stage renal disease in patients with type 2 diabetes and nephropathy, while maintaining overall cardiovascular health.
Effects of a Losartan-Antioxidant Hybrid (GGN1231) on Vascular and Cardiac Health in an Experimental Model of Chronic Renal Failure
GGN1231 shows potential in preventing cardiovascular damage, cardiac hypertrophy, and fibrosis in a rat model of chronic renal failure, with a non-significant 20% reduction in mortality.
Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure.
Enalapril and losartan both equally reduce blood pressure and sympathetic hyperactivity in hypertensive patients with chronic renal failure, supporting the view that AngII-mediated mechanisms contribute significantly to sympathetic hyperactivity.
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.
Greater acute fall in glomerular filtration rate during losartan treatment predicts slower long-term decline in renal function.
Losartan prevents the imbalance between renal dopaminergic and renin angiotensin systems induced by fructose overload. l-Dopa/dopamine index as new potential biomarker of renal dysfunction.
Losartan effectively prevents the imbalance between the renin angiotensin and renal dopaminergic systems induced by fructose overload, preventing hypertension and kidney damage.
Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension.
Long-term use of Losartan effectively lowers blood pressure and reduces proteinuria in renal transplant recipients, with no serious side-effects except for a decrease in haemoglobin.
DOI